Feedback
European Shorting
My Portfolios
Browse Gurus
Print
Email
Salix Pharmaceuticals, Ltd. has a market cap of $2.48 billion; its shares were traded at around $42.09 with a P/E ratio of 11.8 and P/S ratio of 4.6.
This is the annual revenues and earnings per share of SLXP over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of SLXP.
CEO Recent Trades:
- President & CEO Carolyn J Logan sold 25,000 shares of SLXP stock on 12/20/2012 at the average price of 42.27. Carolyn J Logan owns at least 1,035,881 shares after this. The price of the stock has decreased by 0.43% since.
- President & CEO Carolyn J Logan sold 119,300 shares of SLXP stock on 06/28/2012 at the average price of 52.07. Carolyn J Logan owns at least 1,044,488 shares after this. The price of the stock has decreased by 19.17% since.
This is the insider trade history vs. stock price of SLXP. For the complete insider trading history of SLXP, click here.
Directors and Officers Recent Trades:
- Director John F Chappell sold 3,000 shares of SLXP stock on 12/04/2012 at the average price of 42.53. John F Chappell owns at least 493,424 shares after this. The price of the stock has decreased by 1.03% since.
- Director John F Chappell sold 3,000 shares of SLXP stock on 11/21/2012 at the average price of 41.62. John F Chappell owns at least 496,424 shares after this. The price of the stock has increased by 1.13% since.
- Director John F Chappell sold 3,000 shares of SLXP stock on 11/14/2012 at the average price of 41.15. John F Chappell owns at least 499,424 shares after this. The price of the stock has increased by 2.28% since.
- Director Mark A Sirgo sold 3,450 shares of SLXP stock on 11/13/2012 at the average price of 40.53. Mark A Sirgo owns at least 34,955 shares after this. The price of the stock has increased by 3.85% since.
For the complete insider trading history of SLXP, click here.
Subscribe RSS
RSS